Phase III, double-blind, placebo-controlled study of interferon gamma-1b (ACTIMMUNE®) for the treatment of Friedreich’s Ataxia

Ages: 10-25

Location: Children's Hospital of Philadelphia (CHOP), University of Iowa, University of Florida (Gainesville, FL) and UCLA (Los Angeles, CA)

Details: The study is recruiting children and young adults ages 10-25 with Friedreich's Ataxia for a Phase III, double-blind, placebo-controlled clinical trial studying the safety, efficacy, and pharmacokinetics of IFN-γ (interferon gamma-1b, ACTIMMUNE) in FA. This study is funded by Horizon Pharma Ireland, Ltd. and will include approximately 90 patients at four sites in the United States.

For more information, visit the study's site:

Please see the study flyers below and contact the study coordinators listed for each site with any questions.


Note: for potential participants who are under 18 years old, a parent/guardian must first contact the sites to sign up for the study. For potential participants over the age of 18, that individual must sign him/herself up for the study directly.

Children's Hospital of Philadephia (PDF)

University of Iowa (PDF)

University of Florida (PDF)

University of California-Los Angeles (PDF)